Healthcare
BPI France et al. fund new French biotech
BPI France, Ixo Private Equity and the Irdinov fund have backed the creation of new French biotech firm GamaMabs Pharma with a €3.1m investment, working in partnership with French pharma group LFB.
IBB backs Myelo Therapeutics in series-A
IBB Beteiligungsgesellschaft has backed a series-A financing round for pharmaceutical company Myelo Therapeutics.
Sofinnova et al. invest £1.3m in Synthace
Sofinnova Partners has led a ТЃ1.3m funding round for Synthace, a London-based applied synthetic bioengineering company, alongside a syndicate of angel investors.
KfW backs Bill & Melinda Gates Foundation fund with €10m
German development bank KfW has invested €10m in the Global Health Investment Fund (GHIF) of the Bill & Melinda Gates Foundation, joining backers including JP Morgan and GlaxoSmithKline.
French VCs invest €12m in Fermentalg
BPI France, Viveris Management and IRDI have taken part in a €12m fundraising round for biotechnology company Fermentalg, alongside existing investors.
Beaufort Capital exits getemed
Beaufort Capital has sold its 32% stake in medical technology company getemed to the firm’s management.
Industrifonden invests SEK 35m in Smartfish
Industrifonden has acquired a 25% stake in Norwegian clinical nutrition company Smartfish for SEK 35m.
Index leads $20m Egalet round
Index Ventures has led a $20m funding round for Egalet, a pharmaceutical company specialising in the development of abuse-deterrent oral products.
Sector focus: An outbreak of biotech IPOs
Biotech IPOs
Bridgepoint sells Terveystalo to EQT
Bridgepoint has sold Finnish private healthcare provider Terveystalo to EQT for a reported тЌ650m.
Cequr raises $27m in series-B
Swiss biotech firm Cequr has raised $27m in a series-B funding round from two new private investors and all existing backers, including Endeavour Vision and VI Partners.
PE-backed Galantos Pharma sells Alzheimer's drug
Galantos Pharma, a pharmaceutical company backed by High-Tech Gründerfonds (HTGF) and KfW, has sold its Alzheimer's drug Memogain to Neurodyn.
Index Ventures backs series-B round in Mind-NRG
Index Ventures and Belgian life sciences investor LRM have injected a joint €6m into Mind-NRG, a Swiss developer of neuregulins.
HTGF completes hat-trick with perora deal
High-Tech Gründerfonds (HTGF) has invested in perora, a German biotech company – its third investment announced in as many days.
Sofinnova leads CHF 32m round for ObsEva
Sofinnova Partners has led a CHF 32m series-A round for Swiss biopharma company ObsEva.
Sunstone Capital exits Zymenex to Chiesi Group
Sunstone Capital has agreed to sell Danish biopharmaceutical group Zymenex to Italian pharmaceutical company Chiesi Group.
Doughty looks to buy Teknon from Magnum
Doughty Hanson has entered negotiations to acquire Barcelona-based private medical clinic Centro Médico Teknon from Magnum Industrial Capital Partners, according to reports in the Spanish press.
Syncrophi Systems raises €1m
Galway-based medical devices company Syncrophi Systems has raised тЌ1m from the AIB Seed Capital Fund.
Foresight et al. invest in Biofortuna
A consortium of existing backers has injected ТЃ1.3m into Biofortuna, a UK-based molecular diagnostics company, to fund further growth.
St Jude Medical acquires PE-backed Endosense
Medical device company St Jude Medical has wholly acquired Endosense, a medical technology company backed by several private equity firms, for CHF 159m.
EdRip's fourth life sciences fund nears target
Edmond de Rothschild Investment Partners (EdRip) has so far raised €192m for its fourth life sciences fund, BioDiscovery 4, meaning the vehicle is close to reaching its target.
Star Capital sells Alloheim to Carlyle for €180m
Star Capital has sold Alloheim Senioren-Residenzen, a provider of residential care for elderly people in Germany, to fellow private equity house Carlyle for €180m.
EQT backs Swiss Smile
EQT has invested CHF 44m in a later stage growth funding situation involving Switzerland-based dental chain Swiss Smile.
Sovereign Capital's Christchurch Group buys Hunters Moor
Christchurch Group, a neurological rehabilitation platform backed by Sovereign Capital, has bought Hunters Moor, also a provider of neurological rehabilitation services.